203 related articles for article (PubMed ID: 20574412)
1. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old.
Levin MJ; Moscicki AB; Song LY; Fenton T; Meyer WA; Read JS; Handelsman EL; Nowak B; Sattler CA; Saah A; Radley DR; Esser MT; Weinberg A;
J Acquir Immune Defic Syndr; 2010 Oct; 55(2):197-204. PubMed ID: 20574412
[TBL] [Abstract][Full Text] [Related]
2. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine.
Levin MJ; Huang S; Moscicki AB; Song LY; Read JS; Meyer WA; Saah AJ; Richardson K; Weinberg A;
Vaccine; 2017 Mar; 35(13):1712-1720. PubMed ID: 28238631
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM).
Hidalgo-Tenorio C; Ramírez-Taboada J; Gil-Anguita C; Esquivias J; Omar-Mohamed-Balgahata M; SamPedro A; Lopez-Ruz M; Pasquau J
AIDS Res Ther; 2017 Jul; 14(1):34. PubMed ID: 28720147
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
Mugo N; Ansah NA; Marino D; Saah A; Garner EI
Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women.
Kojic EM; Kang M; Cespedes MS; Umbleja T; Godfrey C; Allen RT; Firnhaber C; Grinsztejn B; Palefsky JM; Webster-Cyriaque JY; Saah A; Aberg JA; Cu-Uvin S
Clin Infect Dis; 2014 Jul; 59(1):127-35. PubMed ID: 24723284
[TBL] [Abstract][Full Text] [Related]
6. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine.
Money DM; Moses E; Blitz S; Vandriel SM; Lipsky N; Walmsley SL; Loutfy M; Trottier S; Smaill F; Yudin MH; Klein M; Harris M; Cohen J; Wobeser W; Bitnun A; Lapointe N; Samson L; Brophy J; Karatzios C; Ogilvie G; Coutlée F; Raboud J;
Vaccine; 2016 Sep; 34(40):4799-806. PubMed ID: 27544584
[TBL] [Abstract][Full Text] [Related]
7. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M
Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
[TBL] [Abstract][Full Text] [Related]
9. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.
Gilca V; Sauvageau C; Boulianne N; De Serres G; Crajden M; Ouakki M; Trevisan A; Dionne M
Hum Vaccin Immunother; 2015; 11(3):732-8. PubMed ID: 25714044
[TBL] [Abstract][Full Text] [Related]
10. Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status.
Mugo NR; Eckert L; Magaret AS; Cheng A; Mwaniki L; Ngure K; Celum C; Baeten JM; Galloway DA; Wamalwa D; Wald A
Vaccine; 2018 Nov; 36(46):7025-7032. PubMed ID: 30297124
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
12. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children.
Weinberg A; Song LY; Saah A; Brown M; Moscicki AB; Meyer WA; Bryan J; Levin MJ;
J Infect Dis; 2012 Oct; 206(8):1309-18. PubMed ID: 22859825
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.
Gilca V; Sauvageau C; Boulianne N; De Serres G; Couillard M; Krajden M; Ouakki M; Murphy D; Trevisan A; Dionne M
Hum Vaccin Immunother; 2014; 10(8):2438-45. PubMed ID: 25424952
[TBL] [Abstract][Full Text] [Related]
14. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.
Van Damme P; Meijer CJLM; Kieninger D; Schuyleman A; Thomas S; Luxembourg A; Baudin M
Vaccine; 2016 Jul; 34(35):4205-4212. PubMed ID: 27354258
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants.
Garland SM; Anagani M; Bhatla N; Chatterjee S; Lalwani S; Ross C; Group T; Lin J; Luxembourg A; Walia A; Tu Y
Hum Vaccin Immunother; 2022 Nov; 18(6):2105067. PubMed ID: 35997582
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years.
Maldonado I; Plata M; Gonzalez M; Correa A; Nossa C; Giuliano AR; Joura EA; Ferenczy A; Ronnett BM; Stoler MH; Jin Zhou H; Joshi A; Das R; Bautista O; Group T; Luxembourg A; Saah A; Buchwald UK
Hum Vaccin Immunother; 2022 Nov; 18(5):2078626. PubMed ID: 35853188
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal ≥ HSILs in a Spanish Population of HIV+ MSM Aged > 26 Years.
Hidalgo-Tenorio C; Pasquau J; Omar-Mohamed M; Sampedro A; López-Ruz MA; López Hidalgo J; Ramírez-Taboada J
Viruses; 2021 Jan; 13(2):. PubMed ID: 33498165
[TBL] [Abstract][Full Text] [Related]
18. AIDS Malignancy Consortium 054: Safety and Immunogenicity of the Quadrivalent Vaccine in Indian Women Living With HIV.
Palefsky JM; Poongulali S; Lensing S; Lee J; Da Costa M; Chein A; Beulah F; Murugavel KG; Kumarasamy N
J Acquir Immune Defic Syndr; 2021 Jun; 87(2):875-881. PubMed ID: 33587509
[TBL] [Abstract][Full Text] [Related]
19. Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa.
Mugo N; Eckert LO; Odero L; Gakuo S; Ngure K; Celum C; Baeten JM; Barnabas RV; Wald A
Vaccine; 2021 Jul; 39(33):4751-4758. PubMed ID: 33485644
[TBL] [Abstract][Full Text] [Related]
20. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up.
Chen W; Zhao Y; Xie X; Liu J; Li J; Zhao C; Wang S; Liao X; Shou Q; Zheng M; Saah AJ; Wei L; Qiao Y
Vaccine; 2019 Feb; 37(6):889-897. PubMed ID: 30638797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]